Mylan announces global settlement with Genentech & Roche on TmAb with global licenses (excluding Japan, Brazil and Mexico).
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Bioblast Editor | Mar 14, 2017
Mylan announces global settlement with Genentech & Roche on TmAb with global licenses (excluding Japan, Brazil and Mexico).
By Bioblast Editor | Mar 03, 2017
UK High Court hands down decision in Samsung v Abbvie.
By Bioblast Editor | Mar 02, 2017
PTAB institutes IPR filed by Hospira against Genentech on bevacizumab patents IPR2016-01771 (Patent 7,622,115) and IPR2016-01837 (Patent 7,807,799) from requests filed 9 September 2016.
By Bioblast Editor | Mar 02, 2017
Judge Sleet dismissed Genentech’s suit filed 15 Feb 17 (see below) under Fed Cir’s finding in Amgen v Sandoz.
By Bioblast Editor | Feb 22, 2017
Mundi’s biosimilar rituximab (Truxima®, developed by Celltrion) approved by EMA, and intended for launch in the UK, Germany, Italy, Netherlands, Belgium, Ireland and Luxembourg.
By Bioblast Editor | Feb 15, 2017
Genentech sues Amgen in District Court of Delaware alleging non compliance with BPCIA disclosure obligations in patent dance relating to bevacizumab.
By Bioblast Editor | Jan 27, 2017
Sandoz withdraws EU application for Zioxtenzo, biosimilar pegfilgrastim.
By Bioblast Editor | Jan 27, 2017
CHMP (Committee for Medicinal Products for Human Use) for EMA gives positive opinion for Amgen’s biosimilar adalimumab.
By Bioblast Editor | Dec 22, 2016
Biograstim’s withdrawal of marketing authority, declared by European Commission following voluntary withdrawal from CT Arzneimittel’s biosimilar representative Marketing-Authorisation holder (MAH).
By Bioblast Editor | Dec 19, 2016
Gedeon Richter announces withdrawal of its MA for biosimilar pegfilgrastim.
SUBSCRIBE TO PEARCE IP